Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

For 25 years, the Walk to Defeat ALS® has brought together individuals and families impacted by ALS, offering hope, ...

The unusually contentious bidding war between US private equity firms Bain Capital and KKR for Tokyo-listed Fuji Soft looks ...

Mitsubishi Tanabe Pharma, for over 500 billion yen . This move aligns with Mitsubishi Chemical’s strategy to streamline its operations and concentrate on core sectors such as vehicle electrification, ...

Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 ...

Multiple system atrophy (MSA) is a rare neurological disorder that leads to the progressive deterioration of nerve cells in ...

As global markets navigate uncertainties around tariffs and economic data, investors are seeking stability amid fluctuating indices. In this climate, dividend stocks can offer a reliable income stream ...

DelveInsight's “Menopause Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding ...